Source: Business Wire

Press Release: BPGbio : BPGbio Unveils Research on the Identification of Novel Pancreatic Cancer Patient Subtypes at ASCO GI 2025 Paving the Way for Tailored Treatment

BOSTON--(BUSINESS WIRE)-- #GI25--BPGbio shares results of Project Survival clinical trial identifying novel pancreatic cancer patient subtypes at ASCO GI 2025.

Read full article »

BPGbio's Competitors | BPGbio's News | BPGbio's Financials

Followers on Owler

Est. Annual Revenue

$100K-5.0M

Est. Employees

25-100

President & CEO

Niven R. Narain

CEO Approval Rating

90/100

BPGbio is a Massachusetts-based clinical-stage biopharmaceutical company that offers solutions such as disease mapping and data analytics for the healthcare sector.